Beth E. Dunning

1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(<i>S</i>)-pyrrolidine:  A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties

Edwin B. Villhauer, J. A. Brinkman, Goli B. Naderi et al. · Journal of Medicinal Chemistry · 2003 · 609 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Science +14

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Andrea Mari, William M. Sallas, Yanling He et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 361 citations · Full text

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Niina Matikainen, S. Mänttäri, Anja Schweizer et al. · Diabetologia · 2006 · 334 citations · Full text

Metabolic Syndrome, Cardiovascular Disease, Diabetes +9

The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients

Bogdan Balas, Muhammad R. Baig, Catherine E. Watson et al. · The Journal of Clinical Endocrinology & Metabolism · 2007 · 242 citations

Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

Adrian Vella, Gerlies Bock, Paula D. Giesler et al. · Diabetes · 2007 · 200 citations · Full text